The impact of tacrolimus on vascular endothelial growth factor in experimental corneal neovascularization

Current Eye Research

Volumn 36, Issue 1, 2011, Pages 34-40

  Turgut, Burak ^a   Guler, Mete ^a   Akpolat, Nusret ^a   Demir, Tamer ^a   Celiker, Ulku ^a  

^a FIRAT UNIVERSITY   (Turkey)

Author keywords

Corneal neovascularization; Tacrolimus; VEGF

Indexed keywords

TACROLIMUS; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA ENDOTHELIUM; CORNEA VASCULARIZATION; DRUG EFFECT; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PHOTOGRAPHY; PRIORITY JOURNAL; RAT;

ADMINISTRATION, TOPICAL; ANIMALS; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAPERITONEAL; MALE; RATS; RATS, WISTAR; TACROLIMUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78650453329     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.516620     Document Type: Article

References (43)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
2. Chang JH, Gabison EE, Kato T, et al. Corneal neovascular-ization. Curr Opin Ophthalmol. 2001;12:242-249.
3. Cursiefen C, Kuchle M, Naumann GO. Angiogenesis in corneal diseases: Histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea. 1998;17:611-613.
4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothe-lial growth factor in ocular fuid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
5. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and infammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
6. Phillips GD, Stone AM, Jones BD, et al. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo. 1994;8:961-965.
7. Gan L, Fagerholm P, Palmblad J. Vascular endothelium growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand. 2004;82:557-563.
8. Edelman JL, Castro MR, Wen Y. Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmol Vis Sci. 1999;40:1112-1123.
9. Kim B, Tang Q, Biswas PS, et al. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes. Am J Pathol. 2004;165: 2177-2185.
10. Binetruy-Tournaire R, Demangel C, Malavaud B, et al. Identifcation of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 2000;19:1525-1533.
11. Kvanta A. Ocular angiogenesis: The role of growth factors. Acta Ophthalmol Scand. 2006;84:282-288.
12. Knoll GA, Bell RC. Tacrolimus versus cyclosporine for immunosuppression in renal transplantation: Meta-analysis of randomized trials. BMJ. 1999;318:1104-1107.
13. Cespo-Leiro MG. Tacrolimus in heart transplantation. Transplant Proc. 2003;35:1981-1983.
14. Bhorade SM, Jordan A, Villanueva L, et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. Am J Transplant. 2003;3:1570-1575.
15. Reis A, Reinhard T, Sundmacher R, Braunstein S, Godehardt E. A comparative investigation of FK506 and cyclosporin A in murine corneal transplantation. Graefes Arch Clin Exp Ophthalmol. 1998;236:785-789.
16. Sloper CM, Powell RJ, Dua HS. Tacrolimus in the management of high risk corneal and limbal grafts. Ophthalmology. 2001;108:1838-1844.
17. Cho ML, Cho CS, Min SY, et al. Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fbroblasts. Arthritis Rheum. 2002;46: 1202-1209.
18. Mahoney JM, Waterbury LD. Drug effects on the neovascu-larization response to silver nitrate cauterization of the rat cornea. Curr Eye Res. 1985;4:531-535.
19. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalmol. 2007;91:804-807.
20. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in infamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
21. Kvanta A. Ocular angiogenesis: the role of growth factors. Acta Ophthalmol Scand. 2006;84:282-288.
22. Cursiefen C, Rummelt C, Kuchle M. Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea. 2000;19,526-533.
23. Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci. 1999;40:2115-2121.
24. Miyata S, Ohkuba Y, Mutoh S. A review of the action of tacrolimus (FK506) on experimental models of rheumatoid arthritis. Infamm Res. 2005;54:1-9.
25. Morikawa K, Oseko F, Morikowa S. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. Transplantation. 1992;54:1025-1030.
26. Walgenbach KJ, Kalff JC, Sonmez-Alpan E, et al. Upregulation of basic fbroblast growth factor during chronic rejection of rat intestinal allografts and its downregulation by FK 506. Transplant Proc. 1998;30:2587.
27. Lopez-Ilasaca M, Schiene C, Küllertz G, et al. Effects of FK506-binding protein 12 and FK506 on autophospho-rylation of epidermal growth factor receptor. J Biol Chem. 1998;273:9430-9434.
28. Sengoku T, Kishi S, Sakuma S, et al. FK506 inhibition of histamine release and cytokine production by mast cells and basophils. Int J Immunopharmacol. 2000;22:189-201.
29. Savikko J, Taskinen E, Von Willebrand E. Tacrolimus inhibits platelet-derived growth factor ligand and receptor induction as well as rejection changes in rat renal allografts during long-term follow-up. Transplant Proc. 2002;34:1382.
30. Sasakawa T, Sasakawa Y, Ohkuba Y, et al. FK506 inhibits prostaglandin E2 production from synovial cells by suppressing peripheral blood mononuclear cells. Int Immunopharmacol. 2005;5:1291-1297.
31. Migita K, Maeda Y, Abiru S, et al. Immunosuppressant FK506 inhibits matrix metalloproteinase-9 induction in TNF-alpha-stimulated human hepatic stellate cells. Life Sci. 2006;78:2510-2515.
32. Migita K, Miyashita T, Maeda Y, et al. FK506 suppresses the stimulation of matrix metalloproteinase 13 synthesis by interleukin-1beta in rheumatoid synovial fbroblasts. Immunol Lett. 2005;98:194-199.
33. Sakuma S, Kato Y, Nishigaki F, et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130:1655-1663.
34. Sakuma S, Kato Y, Nishigaki F, et al. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol. 2001;1:749-757.
35. Kong X, Lin Z, Caro J. Immunophilin-ligands FK506 and CsA inhibit HIF1a expression by a VHL- and ubiq-uitin-independent mechanism. FEBS Lett. 2006;580: 6182-6186.
36. Lan CC, Yu HS, Wu CS, et al. FK506 inhibits tumour necrosis factor-alpha secretion in human keratinocytes via regulation of nuclear factor-kappa B. Br J Dermatol. 2005;153:725-732.
37. Kohyama T, Takizawa H, Kawasaki S, et al. A potent immu-nosuppressant FK506 inhibits IL-8 expression in human eosinophils. Mol Cell Biol Res Commun. 1999;1:72-77.
38. Drixler TA, Voest EE, van Vroonhoven TJ, et al. Angiogenesis and surgery: From mice to man. Eur J Surg. 2000;166:435-446.
39. Honma Y, Nishida K, Sotozono C, et al. Effect of transforming growth factor-beta1 and -beta2 on in vitro rabbit corneal epithelial cell proliferation promoted by epidermal growth factor, keratinocyte growth factor, or hepatocyte growth factor. Exp Eye Res. 1997;65:391-396.
40. Freeman MR, Schneck FX, Gagnon ML, et al. Peripheral blood T lymphocytes and lymphocytes infltrating human cancers express vascular endothelial growth factor: A potential role for T cells in angiogenesis. Cancer Res. 1995;55:4140-4145.
41. Gunsilius E, Petzer A, Stockhammer G, et al. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology. 2000;58:169-174.
42. Philip M, Rowley DA, Schreiber H. Infammation as a tumor promoter in cancer induction. Semin Cancer Biol. 2004;14:433-439.
43. Costa C, Incio J, Soares R. Angiogenesis and chronic infam-mation: Cause or consequence? Angiogenesis. 2007;10: 149-166.